

# EUROPEAN MARKET INFRASTRUCTURE REGULATION

## EMIR : RISK MITIGATION



### REGULATION EMIR

#### TIMELINES

##### 15 March 2013

The first "early stage" risk mitigation obligations came into force

##### 15 September 2013

The second group of risk mitigation obligations come into force, namely portfolio reconciliation, dispute resolution and portfolio compression

##### Further information

If you wish to discuss further, please contact the BNP Paribas Fortis European Regulatory Reforms team ([Regreform.be@bnpparibasfortis.com](mailto:Regreform.be@bnpparibasfortis.com)) or your Fixed Income Sales Representative.

This document provides information for clients established in the European Economic Area (EEA) that execute OTC derivative products with BNP Paribas Fortis.

#### SUMMARY OF OBLIGATIONS & DEADLINES:

EMIR introduced a number of risk mitigation obligations with respect to non-cleared OTC derivatives contracts. These obligations are being phased in during the course of 2013 (as set out below) and from 2015 with respect to bilateral margining.

The first "early stage" risk mitigation obligations came into force on 15 March 2013:

- a. The obligation on all financial and non-financial counterparties to obtain timely confirmation of new OTC derivatives transactions. There are no exceptions to this requirement for EU established financial and non-financial counterparties within the scope of EMIR;
- b. The obligation that all financial counterparties and non-financial counterparties (which have crossed the clearing threshold) must begin, if they are not already doing so, conducting daily mark-to-market valuations of non-cleared OTC derivative transactions that are outstanding on or after 15 March 2013.

On 15 September 2013, the second group of risk mitigation obligations come into force, namely portfolio reconciliation, dispute resolution and portfolio compression. These obligations are the immediate focus of this communication.



**BNP PARIBAS**  
**FORTIS**

The bank  
for a changing  
world



## PORTFOLIO RECONCILIATION AND DISPUTE RESOLUTION

### What are our obligations?

- a. The basic requirements are that:
  - » Counterparties must agree processes, either directly with each other or through a qualified third party (such as TriOptima), for portfolio reconciliation (PR) of non-cleared (collateralised or non-collateralised) OTC derivatives; and
  - » Counterparties must also agree on monitoring and dispute resolution (DR) in a timely manner, with a specific escalation process for those disputes that are not resolved within five business days. BNP Paribas Fortis will have to report to its Competent Authority any disputes that are outstanding for more than 15 business days where the amount in dispute is over 15 Million EUR.
- b. These obligations are imposed directly on all EU established financial counterparties (FC), non-financial counterparties (NFC) and non-financial counterparties which exceed the clearing threshold (NFC+) and who enter into OTC derivative contracts which are not cleared.
- c. From 15 September 2013, PR and DR processes should be agreed between counterparties before trading.

The frequency with which PR needs to be undertaken depends upon the classification of the counterparty as an FC/NFC+ or an NFC and the number of trades outstanding between the relevant counterparties:

Counterparty type	Portfolio size	Frequency
Financial or NFC +	• Portfolio => 500 swaps	• Daily
	• 50 swaps > portfolio > 500 swaps	• Weekly
	• Portfolio <= 50 swaps	• Quarterly
NFC	• Portefeuille > 100 swaps	• Quarterly
	• Portefeuille <= 100 swaps	• Annually

### What is portfolio reconciliation?

A portfolio reconciliation process enables two counterparties to undertake a comprehensive review of a portfolio of transactions with a view to identifying any discrepancies of material trade terms.

### What reconciliation options are available?

BNP Paribas Fortis is proposing three options to facilitate compliance with the portfolio reconciliation obligation:

- **One-way delivery (or circularisation):**
  - » BNP Paribas Fortis provides portfolio data to its counterparty
  - » BNP Paribas Fortis' counterparty reviews the portfolio data and identifies discrepancies. In order to facilitate the process, and subject to the relevant regulatory approvals, BNP Paribas Fortis will propose a "negative affirmation" approach (i.e. that the portfolio data is deemed accepted unless discrepancies are identified in a pre-defined timeframe)
  - » Both BNP Paribas Fortis and its counterparty resolve portfolio breaks in a timely fashion.
- **TriOptima adherent reconciliation:**
  - » Each Party provides portfolio data to TriOptima
  - » TriOptima performs a reconciliation of such portfolio data
  - » Each party reviews the portfolio data in accordance with the relevant notice dates or the applicable frequency as set out above
  - » Portfolio breaks to be resolved in a timely fashion.
- **Bilaterally agreed process:**
  - » Each Party provides portfolio data to the other Party in accordance with the notice procedures agreed bilaterally
  - » Either Party performs a reconciliation of such portfolio data (as agreed bilaterally in the documentation between them)
  - » Portfolio breaks to be resolved in a timely fashion.

### What documentation will need to be put in place between BNP Paribas Fortis and its counterparties in relation to portfolio reconciliation and dispute resolution?

ISDA wrote a protocol (ISDA Protocol) which is designed to allow parties to meet the relevant requirements under EMIR. The ISDA Protocol is broad enough to cover relationships in relation to non-cleared OTC Derivatives which are not governed by an ISDA Master Agreement. We encourage parties to adhere to this protocol as this would avoid the need for bilateral negotiation of separate agreements with each of your counterparties (including BNP Paribas Fortis), as long as they too have adhered to this protocol. We would also note that other industry bodies are contemplating documentation in this regard for other local law governed OTC documentation, though these initiatives are still under discussion.



## PORTFOLIO COMPRESSION

### What are our obligations?

- a. EMIR imposes an obligation on all FC, NFC and NFC+ counterparties established in the EU, who have 500 or more non-cleared OTC derivative contracts outstanding with a counterparty, to have in place procedures to regularly analyse the possibility to compress their portfolio in order to reduce their counterparty credit risk.
  - » This portfolio compression analysis must be performed at least twice a year.
- b. If an FC, NFC or NFC+ concludes that portfolio compression is not appropriate, it must be able to provide a reasonable and valid explanation to its relevant competent authority for such conclusion, for example, that the portfolio is purely directional and does not allow any offsetting transactions or multilateral compression services are not available in the relevant markets or products.
- c. Portfolio compression does not prevent an offsetting transaction from being concluded with a counterparty that is different from the counterparty in the initial transaction.

### What is a compression?

Portfolio compression is an exercise by which two (bilateral compression) or several (multilateral compression) entities attempt to reduce the total gross notional and the number of outstanding non-cleared OTC derivatives trades without changing the risk exposure and present value of the portfolio. This is achieved by the termination of existing trades and their replacement by a smaller number of new trades (potentially with a different counterparty when undertaken on a multilateral basis).

### What is BNP Paribas Fortis doing?

BNP Paribas Fortis is currently conducting an internal analysis to identify impacted counterparties. To comply with its EMIR obligations, BNP Paribas Fortis will conduct regular analysis of the portfolios of outstanding non-cleared OTC derivatives with its counterparties. The purpose of this exercise is to identify the potential compression opportunities prior to contacting their counterparty to organise it. Do not hesitate to contact us should you have any question relating to this process.

### What documentation will need to be put in place between BNP Paribas Fortis and its counterparties?

The industry bodies have not produced any protocol or specific documentation to address trade compression concerns. Should you choose to go through entities such as Trioptima to perform your compression, we expect them to provide you with their own standard terms and conditions to which you will have to sign up. Where clients do not have the facility or systems to interface with Trioptima (and others) directly, bilateral compression with BNP Paribas Fortis will be required. BNP Paribas Fortis will assist in processing your compression on a bilateral basis. Terms and conditions will be agreed at the time of the portfolio analysis based on the population of trades you have with us.

### DISCLAIMER

This document is edited and distributed by BNP Paribas Fortis SA/NV, with registered office at Montagne du Parc/Warandeborg 3, 1000 Brussels, Belgium (the "Bank"). The information in this document is confidential. It may not under any circumstances be copied, reproduced, distributed or divulged to third parties (other than your advisers acting in their professional capacity), either wholly or in part, without the Bank's prior written consent.

This document is a marketing communication. The information in this document has not been obtained in accordance with the statutory and regulatory requirements that aim to guarantee the publication of objective and independent investment-related research. It may not, therefore, be considered as an objective description of the matters to which it refers.

This document is provided for information purposes only and does not constitute an offer, or an invitation to make an offer, for the sale or purchase of any financial instrument or subscription thereto in any jurisdiction, and it does not constitute a prospectus as referred to in the rules applicable to offering financial instruments or permitting trading therein.

This document has not been, and shall not be, approved or ratified by a supervisory authority in any jurisdiction.

This document does not constitute investment, legal, tax or accounting advice.

Although the Bank has taken reasonable measures to ensure that the information included in this document is accurate, clear and not misleading, neither the Bank nor its affiliated companies, directors, consultants or employees accept any liability for any inaccurate, incomplete or missing information or for any direct or indirect damage, losses, costs, claims, liabilities or other expenses that arise in any way from the use of or reliance on the information in this document.

The Bank reserves the right to alter the information in this document without prior notice and is not obliged to notify you of any such alterations.

BNP Paribas Fortis SA/NV comes under the prudential supervision of the National Bank of Belgium, Boulevard de Berlaimont/De Berlaimontlaan 14, 1000 Brussels and, as regards investor and consumer protection, the Financial Services and Markets Authority (FSMA), Rue du Congrès/Congresstraat 12-14, 1000 Brussels, and is registered as an insurance agent with the FSMA under No. 25879 A.